Are on-body wearable injectors the future of large-volume drug delivery, or will formulation and device advances keep creating alternatives?
Aaron Mann, CEO of Windgap Medical joins Nick Capman to compare the approaches and explain where he thinks the line between handheld and wearable delivery will settle.
In this episode:
Why about 2 mL has historically pushed doses toward wearables
How formulation, enzyme-assisted delivery, and device design compare
The advantages and trade-offs of enzyme-assisted approaches
Why the 3 to 10 mL range has become so important
What a recent wearable-to-autoinjector approval does and doesn’t show
Where wearables remain the better choice
The costs of committing too early to the wrong delivery format
Five questions to answer before choosing a wearable
About Aaron Mann
Aaron Mann is CEO of Windgap Medical, which develops handheld autoinjector platforms for complex injectables. He was previously CEO of Kindeva Drug Delivery, President of Drug Delivery Systems at 3M, and Vice President of Corporate Development and Strategy at Phillips-Medisize. He holds an MBA from Harvard Business School and a BA from Carleton College.
About The FDA Group
The FDA Group helps life science organizations rapidly access the industry’s best consultants, contractors, and candidates. Our resources assist in every stage of the product lifecycle, from clinical development to commercialization, with a focus on staff augmentation, auditing, remediation, QMS, and other specialized project work in Quality Assurance, Regulatory Affairs, and Clinical Operations. Learn more: https://www.thefdagroup.com/
